Orchestra BioMed Holdings, Inc. Share Price & Technical Analysis
OBIO · $4.06 (-0.98%)
Healthcare / Biotechnology
$4.06
-0.98%
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops…
Price chart
Seasonality
May has 1 positive and 2 negative years (last 5 years shown)
0% return in May, 13% avg return in past 3 year May month.
2% return in 2026, 26% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -17% | 26% | 0% | -7% | 0% | – | – | – | – | – | – | – | 2% |
| 25 | 18% | -8% | -9% | -23% | -10% | -7% | 19% | 0% | -7% | 56% | 39% | -19% | 50% |
| 24 | -21% | -10% | -18% | -17% | 57% | 14% | -9% | -8% | -24% | 2% | 12% | -29% | -51% |
| 23 | -13% | 13% | 100% | -20% | -8% | -54% | -14% | 5% | 38% | -47% | 32% | 47% | 79% |
| 22 | 0% | 0% | 0% | 0% | 0% | 1% | -1% | -1% | 1% | 1% | -1% | 1% | 1% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$232.34M
P/E ratio
—
52W high
$5.42
52W low
$2.20
Volume
1,98,269
Beta
0.52
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Orchestra BioMed Holdings, Inc. share price today?
- Orchestra BioMed Holdings, Inc. (OBIO) last traded around $4.06 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does OBIO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OBIO. Download the app for real-time alerts.
- How can I analyze Orchestra BioMed Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.